• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    PCI Pharma Services

    Cytovance Biologics

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Flow Sciences

    Baxter BioPharma Solutions

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    New Drug Development Strategies Needed for Alzheimer’s Treatments

    Selecting a single CRO partner that can take CNS compounds from functional screening in vitro through in vivo and beyond

    New Drug Development Strategies Needed for Alzheimer’s Treatments
    Related CONTENT
    • Charles River & CHDI Extend Partnership
    • Celgene Enters AI Drug Discovery Deal with Exscientia
    • Biogen, Eisai End Phase III aducanumab Trials in AD
    • Servier & Oncodesign Partner for Parkinson's
    • WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal
    Birgit Hutter-Paier, Senior Director and Head of Neuropharmacology, QPS05.10.19
    Today, 50 million people worldwide are living with Alzheimer’s disease or a related form of dementia. That number is expected to more than triple to 152 million by 2050. 
     
    With Alzheimer’s disease becoming more prevalent by the day, it is essential the drug discovery and development industry refocus its efforts on new strategies to achieve much needed pharmaceutical breakthroughs.
     
    During the last decade, drug development for Alzheimer’s has focused primarily on treating the disease and its symptoms. It’s time we step back and focus on discovering the cause of the disease and developing drugs that delay or, ideally, prevent the onset of the Alzheimer’s.
     
    This shift is already in effect.  Today, the world’s most prominent scientists are expanding their focus beyond amyloid and tau, both playing their roles in this devastating disease, to new strategies centered around detecting Alzheimer’s while it’s in the silent biological stage. Some groups are investigating cell stress, others are investigating brain inflammation, lipid metabolism, the importance of neurofilaments or small brain lesions.  There are many promising mechanisms that could be ‘druggable;’ the focus is now on finding and testing more targets to determine how to prevent the onset of Alzheimer’s disease.
     
    Ultimately, treating Alzheimer's will likely involve a combination of therapies. For example, it could mean treating amyloid and inflammation of the brain in parallel. It’s still early days for combination therapies; however, repurposing a known drug and combining it with a new drug is one strategy that may prove successful.
     
    This is a strategy that has legs and promises even greater success as the industry receives approvals for medicines in other areas, such as for autoimmune diseases. Success with other drugs will open more doors for research in Alzheimer’s disease because we’ll have more new drugs to test as we explore new combination therapies.
     
    Regardless of which new strategies are being explored, all new compounds must move from functional screening in vitro through in vivo and beyond.  One of the biggest mistakes I see companies make as they work to advance compounds from in vitro to in vivo is testing models that aren’t closely aligned. This happens most often when companies use one partner to conduct in vitro studies and then use a different partner to conduct in vivo studies. 
     
    Working with a single CRO for early development is crucial because in vitro and follow-on in vivo studies can be designed using closely related models to, for instance, ensure the expressions of targets are the same. 
     
    The closer the in vitro model is to the in vivo model, the better the outcome. When in vitro studies are designed in a vacuum, it makes in vivo studies less predictable and the outcomes often suffer. Conversely, when companies choose a partner with proven animal models and cell models that match, the outcomes are better. For example, a mouse model expressing the same gene construct as the cell line ensures compounds are tested in in vitro and in vivo models with the same promoter, expressing the same protein fragment, with the same mutations, meaning ultimately with the same phenotype.
     
    Fortunately, we’re seeing this shift to new strategies with the hundreds of small biotech companies focused on developing potential new CNS drugs and large pharmaceutical and biotech companies continuing to demonstrate commitment to developing disease-modifying treatments for Alzheimer's.  We’re also witnessing a positive trend of more compounds moving to late-phase development as more companies choose to partner with a single high-quality CRO to ensure their in vitro and in vivo test models are closely aligned. 
     
    CRO Selection Checklist
    Don’t underestimate the importance of CRO selection. CNS drug development is a high stakes job that requires a CRO partner that can help pharmaceutical and biotech companies overcome the challenges that arise when exploring new, innovative drug development strategies and taking compounds from functional screening in vitro through in vivo and beyond.
     
    Use the CRO Selection Checklist below to help you vet CROs for your next CNS drug development project:
     
    Experience
    CRO should:
    •  Have deep experience in CNS disorders and decades of historical data to help guide your study.
    •  Have tested thousands of CNS compounds, with many of them moving to late-phase development.
    CNS Disease Models
    CRO should:
    • Have several Alzheimer's, Parkinson’s and other CNS disease models.
    • Have models that are proven to work, as evidenced by moving compounds to the next phase.
    • Excel at designing in vitro and follow-on in vivo studies using closely related models.
    Hands-On Scientists
    CRO should:
    • Have experienced scientists doing the work.
    • Have hands-on scientists who are available and equipped to make study design and testing recommendations.
    • Ensure the same team of scientists follows the study from in vitro to in vivo, making recommendations such as the duration of treatment or which positive controls to use.

    Birgit Hutter-Paier, Senior Director and Head of Neuropharmacology for QPS, established and managed the preclinical research group at QPS, which consists of highly experienced and professional members at associate and scientist levels. Hutter-Paier has extensive experience in life-science research and development, covering drug discovery and project management where she has directed multiple diverse and concurrent projects from early preclinical stage to pharmacology. During the last 15 years, her team at QPS has tested approximately 2,000 compounds specific to neurodegeneration and neuropathology, with nearly 50 of these compounds advancing to clinical development.
    Related Searches
    • study
    • it
    • Preclinical
    • CRO
    Suggested For You
    Charles River & CHDI Extend Partnership Charles River & CHDI Extend Partnership
    Celgene Enters AI Drug Discovery Deal with Exscientia Celgene Enters AI Drug Discovery Deal with Exscientia
    Biogen, Eisai End Phase III aducanumab Trials in AD Biogen, Eisai End Phase III aducanumab Trials in AD
    Servier & Oncodesign Partner for Parkinson Servier & Oncodesign Partner for Parkinson's
    WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal WuXi STA, Ark Biosciences Sign CMC Devt. & Mfg. Deal
    AbbVie, Voyager Expand Parkinson AbbVie, Voyager Expand Parkinson's Pact
    IFM Therapeutics Launches Subsidiary IFM Therapeutics Launches Subsidiary
    Next-Gen Translational Medicine Next-Gen Translational Medicine
    QPS Expands Translational Medicine Division QPS Expands Translational Medicine Division
    Kamada Appoints R&D VP Kamada Appoints R&D VP
    QPS Launches New Brand Identity QPS Launches New Brand Identity
    NeuroBo Pharmaceuticals to Initiate Phase 3 Trial NeuroBo Pharmaceuticals to Initiate Phase 3 Trial
    Biogen Expands Neurological Disease R&D Biogen Expands Neurological Disease R&D
    Rentschler Biopharma Appoints Innovation SVP Rentschler Biopharma Appoints Innovation SVP
    Evotec & LEO Pharma Partner for Drug Discovery Evotec & LEO Pharma Partner for Drug Discovery

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20


    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20


    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20

    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login